Posted by Michael Wonder on 13 Oct 2020
Oxular receives rare paediatric disease and orphan drug designations for retinoblastoma treatment
12 October 2020 - Provides furthered momentum for OXU-003 development programme.
Oxular Limited today announces it has received both rare paediatric disease and orphan drug designations from the U.S. FDA for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.
Oxular's OXU-003 programme for the treatment of retinoblastoma consists of a proprietary anti-tumour drug which utilises Oxular's formulation and ocular administration technology to safely deliver a precise amount of drug adjacent to the primary ocular tumour (local or targeted chemotherapy). OXU-003 has been shown to be effective as a stand-alone therapy in pre-clinical models and is complementary with other agents currently used to treat retinoblastoma.
